Quick Listen: Scrip's Five Must-Know Things
Executive Summary
In this week's podcast version of Five Must-Know Things: Genmab confident in CD20xCD3 battle; Alzheimer’s disappointment for Roche; Japan speed bump for Shionogi’s oral COVID antiviral; pharma’s view of psychedelics; and a roundup of key BIO sessions.
Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by Scrip's global team, in this podcast version of Five Must-Know Things.
This episode covers insights for the business week ended 24 June 2022, including: Genmab A/S confident in CD20xCD3 battle; Alzheimer’s disappointment for Roche Holding AG; Japan speed bump for Shionogi & Co. Ltd.’s oral COVID antiviral; pharma’s view of psychedelics; and a roundup of key BIO sessions.
This and all our other podcasts are available on the Pharma Intelligence channel on Apple Podcasts, Google Podcasts, SoundCloud, TuneIn and Spotify Podcasts, and via smart speakers if one of these platforms has been set up as your default podcast provider.
Stories mentioned in this episode:
(Also see "Genmab Confident It Has Edge Over Roche In Bispecific Battle" - Scrip, 17 Jun, 2022.)
(Also see "Failure Of Roche’s Nine-Year Alzheimer’s Prevention Study Disappointing, But No Surprise" - Scrip, 16 Jun, 2022.)
(Also see "Shionogi Hit By Surprise Japan Road Bump For Oral COVID Drug" - Scrip, 22 Jun, 2022.)
(Also see "More De-Risking Required Before Pharma Dives Into Psychedelics" - Scrip, 20 Jun, 2022.)
(Also see "BIO 2022 Notebook: Future Directions For R&D" - Scrip, 16 Jun, 2022.)